PRGO:NYSEPerrigo Company plc Analysis
Data as of 2026-08-23 - not real-time
$14.25
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Perrigo Company plc is priced at $14.25, and its moving averages give no clean directional read — the structure is neutral. Over a rolling month the price has gained 39.4%. RSI sits at 71.6, which reads as overbought, and MACD momentum is bullish. Watch $10.01 as support and $14.26 as the nearer resistance level.
Multiples put this in undervalued territory: 5.9 times earnings against the sector's 31.1. Sell-side targets cluster 15.8% above the current quote. Revenue is contracting at 3.2% on a -41.9% profit margin. The 8.14% dividend yield looks stretched against payout coverage.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 77.8%, a beta of 1.05 and a maximum drawdown of 62.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 2/10.
Multiples put this in undervalued territory: 5.9 times earnings against the sector's 31.1. Sell-side targets cluster 15.8% above the current quote. Revenue is contracting at 3.2% on a -41.9% profit margin. The 8.14% dividend yield looks stretched against payout coverage.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 77.8%, a beta of 1.05 and a maximum drawdown of 62.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 2/10.
Top Market Events
Perrigo Co PLC PRGO navigates a challenging quarter with strategic wins in infant formula and innovation, despite a 3.Perrigo Company plc NYSE: PRGO , a leading provider of consumer self-care products, today announced that it plans to...14dPerrigo Q2 Earnings Call HighlightsPerrigo NYSE:PRGO reported second-quarter 2026 results that exceeded its internal...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- RSI at 71.6 signals overbought conditions
- Trading above the 200-day average of 12.22
- MACD momentum is positive
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- RSI at 71.6 signals overbought conditions
- P/E of 5.9 versus sector average of 31.1
- Dividend yield of 8.14% looks stretched against payout coverage
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- P/E of 5.9 versus sector average of 31.1
- Dividend yield of 8.14% looks stretched against payout coverage
- Negative profit margin of -41.9%
Key Metrics & Analysis
Financial Health
Revenue Growth-3.20%
Profit Margin-41.85%
P/E Ratio5.9
ROE-48.75%
ROA1.97%
Debt/Equity138.18
P/B Ratio0.8
Op. Cash Flow$196.1M
Free Cash Flow$437.2M
Industry P/E31.1
Technical Analysis
TrendNeutral
RSI71.6
Support$10.01
Resistance$14.26
MA 20$12.16
MA 50$11.09
MA 200$12.22
MACDBullish
VolumeDecreasing
Fear & Greed Index94.41
Valuation
Fair Value$18.15
Target Price$16.50
Upside/Downside15.79%
GradeUndervalued
TypeValue
Dividend Yield8.14%
Risk Assessment
Beta1.05
Volatility77.80%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.